Synthetic research peptide catalogued for repair-and-recovery pathway studies.
- Dose
- 10 mg
- Batch
- 268001
BPC-157
BPC-157 (Body Protection Compound-157; bepecin; PL-14736 / PL-10 / PLD-116) — synthetic pentadecapeptide, partial sequence of body protection compound · GEPPPGKPADDAGLV
For research purposes only — This compound is not FDA approved. All data presented is from clinical trials for educational reference.
Synthetic research peptide catalogued for repair-and-recovery pathway studies.
Members get 10% off every order, on top of volume pricing — become a member with a free account.
Volume savings are applied automatically at checkout. Larger orders: support@alptide.at
- Lab
- Janoshik Analytical
- Purity
- 99.963%
- Methods
- HPLC · LC-MS
- Tested
- Oct 6, 2026
For laboratory research use only. Not for human consumption.
Technical specifications
- Type
- Peptide
- Scientific name
- BPC-157 (Body Protection Compound-157; bepecin; PL-14736 / PL-10 / PLD-116) — synthetic pentadecapeptide, partial sequence of body protection compound
- Amino acids
- 15
- Sequence
- GEPPPGKPADDAGLV
- Molecular weight
- 1419.5 g/mol
- Formula
- C62H98N16O22
- CAS
- 137525-51-0
- Origin
- A 15-residue partial sequence of body protection compound (BPC), a protein isolated from human gastric juice; first characterized by Sikiric and colleagues in 1993.
- Lyophilized (powder)
- -20°C · stable long-term; protect from light and moisture
- Reconstituted
- 2-8°C · use within 30 days; avoid repeated freeze-thaw cycles
- Room temperature
- Lyophilized powder tolerates short-term ambient shipping, but prolonged storage above 4°C accelerates hydrolysis and aggregation. Reconstituted solutions should not be left at room temperature. Note: the published literature describes BPC-157 as unusually stable in aqueous solution and in human gastric juice relative to other peptides — this is a reported physicochemical property, not a substitute for cold-chain handling of research material.
Peer-reviewed research
Published research and registered trials involving this compound. Provided for educational reference only — none of it is a claim about this product.
- Journal of Physiology (Paris)A new gastric juice peptide, BPC. An overview of the stomach-stress-organoprotection hypothesis and beneficial effects of BPCSikirić P, Petek M, Rucman R, Seiwerth S, Grabarević Z, Rotkvić I, Turković B, Jagić V, Mildner B, Duvnjak M, et al.1993DOI: 10.1016/0928-4257(93)90038-uPMID: 8298609
- Journal of Orthopaedic ResearchEffective therapy of transected quadriceps muscle in rat: Gastric pentadecapeptide BPC 157Staresinic M, Petrovic I, Novinscak T, Jukic I, Pevec D, Suknaic S, Kokic N, Batelja L, Brcic L, Boban-Blagaic A, Zoric Z, Ivanovic D, Ajduk M, Sebecic B, Patrlj L, Sosa T, Buljat G, Anic T, Seiwerth S, Sikiric P2006DOI: 10.1002/jor.20089PMID: 16609979
- Journal of Applied Physiology (1985)The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migrationChang CH, Tsai WC, Lin MS, Hsu YH, Pang JH2011DOI: 10.1152/japplphysiol.00945.2010PMID: 21030672
- Journal of Molecular Medicine (Berlin)Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulationHsieh MJ, Liu HT, Wang CN, Huang HY, Lin Y, Ko YS, Wang JS, Chang VH, Pang JS2017DOI: 10.1007/s00109-016-1488-yPMID: 27847966
- Current Pharmaceutical DesignNovel Cytoprotective Mediator, Stable Gastric Pentadecapeptide BPC 157. Vascular Recruitment and Gastrointestinal Tract HealingSikiric P, Rucman R, Turkovic B, Sever M, Klicek R, Radic B, Drmic D, Stupnisek M, Misic M, Vuletic LB, Pavlov KH, Barisic I, Kokot A, Peklic M, Strbe S, Blagaic AB, Tvrdeic A, Rokotov DS, Vrcic H, Staresinic M, Seiwerth S2018DOI: 10.2174/1381612824666180608101119PMID: 29879879
- Gut and LiverStable Gastric Pentadecapeptide BPC 157, Robert's Stomach Cytoprotection/Adaptive Cytoprotection/Organoprotection, and Selye's Stress Coping Response: Progress, Achievements, and the FutureSikiric P, Hahm KB, Blagaic AB, Tvrdeic A, Pavlov KH, Petrovic A, Kokot A, Gojkovic S, Krezic I, Drmic D, Rucman R, Seiwerth S2020DOI: 10.5009/gnl18490PMID: 31158953
- ClinicalTrials.gov registry record NCT02637284 (PharmaCotherapia d.o.o.)Phase I, Pilot Study in Healthy Volunteers, to Assess the Safety and Pharmacokinetics of PCO-02, Which Active Ingredient is BPC-157, a Penta-deca-peptide From Gastric SourcePharmaCotherapia d.o.o. (lead sponsor); single-centre study, Hospital Ángeles Tijuana, Mexico2015
Researcher reviews
“I cross-checked the published HPLC against an independent lab. Numbers lined up. This is the transparency the space has been missing.”
More in Repair
TB-500
10 mg / vial
Synthetic research peptide catalogued for repair-and-recovery pathway studies.
AHK-Cu
50 mg / vial
Copper-complexed peptide research material catalogued for tissue-model studies.
BPC-157 + TB-500
20 mg / vial
Combined research-peptide blend catalogued for repair-and-recovery pathway studies.
Glow Blend
70 mg / vial
Named multi-peptide research blend catalogued for repair-and-recovery studies.